The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy: Long-term Follow-up of a 2-Year Randomized Clinical Trial
Abstract
IMPORTANCE: Short-term outcome studies of antipsychotic dose-reduction/discontinuation strategies in patients with remitted first-episode psychosis (FEP) showed higher relapse rates but no other disadvantages compared with maintenance treatment; however, long-term effects on recovery have not been studied before. OBJECTIVE: To compare rates of recovery in patients with remitted FEP after 7 years of follow-up of a dose reduction/discontinuation (DR) vs maintenance treatment (MT) trial. DESIGN: Seven-year follow-up of a 2-year open randomized clinical trial comparing MT and DR. SETTING: One hundred twenty-eight patients participating in the original trial were recruited from 257 patients with FEP referred from October 2001 to December 2002 to 7 mental health care services in a 3.2 million-population catchment area. Of these, 111 patients refused to participate and 18 patients did not experience remission. PARTICIPANTS After 7 years, 103 patients (80.5%) of 128 patients who were included in the original trial were located and consented to follow-up assessment. INTERVENTION: After 6 months of remission, patients were randomly assigned to DR strategy or MT for 18 months. After the trial, treatment was at the discretion of the clinician. MAIN OUTCOMES AND MEASURES: Primary outcome was rate of recovery, defined as meeting the criteria of symptomatic and functional remission. Determinants of recovery were examined using logistic regression analysis; the treatment strategy (MT or DR) was controlled for baseline parameters. RESULTS: The DR patients experienced twice the recovery rate of the MT patients (40.4% vs 17.6%). Logistic regression showed an odds ratio of 3.49 (P = .01). Better DR recovery rates were related to higher functional remission rates in the DR group but were not related to symptomatic remission rates. CONCLUSIONS AND RELEVANCE: Dose reduction/discontinuation of antipsychotics during the early stages of remitted FEP shows superior long-term recovery rates compared with the rates achieved with MT. To our knowledge, this is the first study showing long-term gains of an early-course DR strategy in patients with remitted FEP. Additional studies are necessary before these results are incorporated into general practice. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN16228411.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“That is, relapses are not distributed evenly across time but tend to occur predominantly around the point of drug cessation.”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“It appears that relapse rates are raised in the discontinuation group for 1–3 years following a switch to placebo, before converging with relapse rates of medicated patients thereafter.3,56–59”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
In the citing paper
“one found 43% of the original cohort of patients relapsed in the first year, 21.5% in the second year, and just 3.7% a year in each of the 5 years following57,61”
From A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse (2021) · cites this paper as [57]
Citations
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
The Dopamine Hypothesis of Schizophrenia: Version III--The Final Common Pathway
Howes, O. D., & Kapur, S. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp006 · Cited by 2,693
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
Andreasen, N. C., Carpenter, W. T., Kane, J. M., Lasser, R. A., Marder, S. R., & Weinberger, D. R. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.3.441 · Cited by 2,350
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.1 · Cited by 1,350
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia
Lewis, D. A., Curley, A. A., Glausier, J. R., & Volk, D. W. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.10.004 · Cited by 1,071
Neuroleptic Withdrawal in Schizophrenic Patients
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 434
Wunderink, L., Nienhuis, F. J., Sytema, S., Slooff, C. J., Knegtering, R., & Wiersma, D. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0502 · Cited by 234
Self-citationGrace, A. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.011 · Cited by 225
Cited by
Sorted by citations
Items 401–500 of 567
The effects of drug safety warnings on drug sales and share prices
Bialkowski, J. P., & Clark, J. (2021) · Health Economics · doi:10.1002/hec.4440 · Cited by 2
Bergström, T., & Gauffin, T. (2023) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgad032 · Cited by 2
Somatische Morbidität psychisch Kranker
Hewer, W., Schneider, F. W., & Schneider, F. W. (2011) · Springer eBooks · doi:10.1007/978-3-642-17192-5_42 · Cited by 2
Stupak, R. (2020) · Diametros · doi:10.33392/diam.1260 · Cited by 5
Tasch, G., & Gøtzsche, P. C. (2023) · Psychosis · doi:10.1080/17522439.2023.2183428 · Cited by 2
Lim, C., Paudel, S., Holt, D. J., & Freudenreich, O. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00027-8 · Cited by 2
Watson, T. T. (2014) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.16.1.51 · Cited by 2
Tibaldi, G. (2016) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2016-002004 · Cited by 2
Opium and the People: The Prescription Psychopharmaceutical Epidemic in Historical Context
Moncrieff, J. (2017) · The Sedated Society · doi:10.1007/978-3-319-44911-1_4 · Cited by 2
Kva klinisk nytte har me av dagens psykiatriske diagnosar - og kva er alternativet?
Aarre, T. F., & Larsen, K. Ø. (2017) · Tidsskrift for psykisk helsearbeid · doi:10.18261/issn.1504-3010-2017-01-02 · Cited by 2
Kim, G., & Jung, E. (2018) · Journal of Korean Academy of Psychiatric and Mental Health Nursing · doi:10.12934/jkpmhn.2018.27.1.28 · Cited by 2
Psychotherapy in schizophrenia: a retrospective controlled study
Haram, A., Jonsbu, E., Fosse, R., Skårderud, F., & Hole, T. (2018) · Psychosis · doi:10.1080/17522439.2018.1460392 · Cited by 2
Introduction à la classification des psychoses endogènes de Karl Leonhard
Foucher, J., Elowe, J., & Berna, F. S. (2020) · Elsevier eBooks · doi:10.1016/b978-2-294-77128-6.00018-8 · Cited by 2
Medication‐free treatment for psychosis – an alternative to antipsychotics?
Chakraborty, N. (2021) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.730 · Cited by 2
Dimensions and Course of Clinical Recovery in Schizophrenia and Related Disorders
Carpiniello, B., Pinna, F., Manchia, M., & Tusconi, M. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_1 · Cited by 2
Bonsack, C., Favrod, J., & Morandi, S. (2016) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2016.08.013 · Cited by 2
Fountoulakis, K. Ν., Panagiotidis, P., & Nimatoudis, I. (2019) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2712 · Cited by 2
Medication management of antipsychotic treatment in schizophrenia—A narrative review
Isohanni, M. K., Jääskeläinen, E., Miller, B. J., Hulkko, A., Tiihonen, J., Möller, H., Hartikainen, S. A., Huhtaniska, S., & Lieslehto, J. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2765 · Cited by 2
Prescription for Critical Thinking: A Discussion of Psychotropic Medication and Counseling
Biggs, B. W. (2015) · JMU Scholoraly Commons (James Madison University) · Cited by 2
Dose reduction, relapse and functional recovery in first episode psychosis
Killackey, E. J. (2017) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867417700276 · Cited by 2
Guest editorial: Special issue on maintenance treatment in schizophrenia.
Emsley, R. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.03.029 · Cited by 2
New treatments for psychotic disorders
Nieman, D. H. (2015) · The Lancet Psychiatry · doi:10.1016/s2215-0366(15)00093-0 · Cited by 1
Eck, R. M. V., Jelsma, A., Blondeel, J., de Wilde-Schutten, K., Zondervan, J., Burger, T. J., Vellinga, A., de Koning, M. B., Schirmbeck, F. N., Gerritsen, S., et al. (2025) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-025-02872-w · Cited by 1
Nyttingnes, O., Hofstad, T., Johnsen, E., Strømme, M. F., Markussen, S., Killackey, E. J., Rinaldi, M., Blindheim, A. A., McDaid, D., Brinchmann, B., et al. (2025) · F1000Research · doi:10.12688/f1000research.166156.1 · Cited by 1
Orlando, S., Long, M., Akther-Robertson, J., Stansfeld, J. L., Haime, Z., Smith, R., Moncrieff, J., & Morant, N. J. (2025) · Journal of Mental Health · doi:10.1080/09638237.2025.2585195 · Cited by 1
Leucht, S., & Rodolico, A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00699-7 · Cited by 1
Ricci, V., Sarni, A., Barresi, M., Remondino, L., Martinotti, G., & Maina, G. (2026) · Brain Sciences · doi:10.3390/brainsci16060550 · Cited by 1
Lu, C., Dong, Y., Zhai, Z., Gao, T., Luo, M., Chang, D., Chen, J., Xue, J., Zhao, Y., Xiang, Q., et al. (2026) · Psychological Medicine · doi:10.1017/s0033291726104024 · Cited by 1
Jobe, T. H., & Harrow, M. (2014) · Evidence-Based Mental Health · doi:10.1136/eb-2014-101803 · Cited by 1
Working Towards A UK Randomized Controlled Trial of Psychodynamic Therapy for Psychosis
Summers, A. (2015) · British Journal of Psychotherapy · doi:10.1111/bjp.12175 · Cited by 1
Boshes, R. A., & Manschreck, T. C. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.02.023 · Cited by 1
Recovery-Related Brief Interventions for Psychosis
Shepherd, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-30521-9_9 · Cited by 1
White Paper: Brain Scan Research
Hunter, N., & Schultz, W. (2016) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.18.1.9 · Cited by 1
Freudenreich, O. (2019) · Current clinical psychiatry · doi:10.1007/978-3-030-29450-2_11 · Cited by 1
Antipsychotic-Related Mortality
Cohen, D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803376-0.00015-0 · Cited by 1
Hunter, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-91752-8_3 · Cited by 1
Jäger, M. (2018) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-0590-4147 · Cited by 1
Moving Beyond Current Treatment: Responding to Extreme States With Compassion and Dignity
Mackey, C. (2022) · Journal of Humanistic Psychology · doi:10.1177/00221678221078659 · Cited by 1
Depot-Antipsychotika in der Rezidivprophylaxe
(2014) · psychopraxis neuropraxis · doi:10.1007/s00739-014-0218-x · Cited by 1
Llovera, N. F., Ramos, P. R. G., & Ballesteros, A. A. (2015) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2015.08.004 · Cited by 1
Research on maintenance treatment to prevent relapse of psychotic disorders
Hui, C. L. M. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114928 · Cited by 1
Schizophrenia and Other Primary Psychotic Disorders
Lawrence, R. E., Becker, I., & McGorry, P. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_104-1 · Cited by 3
Drug Treatment of the Psychoses
Rogers, J. P., Chesney, E., Morrison, P., & Gaughran, F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.012 · Cited by 1
Causes and Outcome of Psychosis
Casetta, C., Kępińska, A. P., Stilo, S. A., & Murray, R. M. (2024) · Cambridge University Press eBooks · doi:10.1017/9781911623861.011 · Cited by 1
Issues Arising in the Application of the CRPD in Practice - Case Histories
Gill, N., Sartorius, N., Sunkel, C., Savage, M., Amering, M., Evans, M., Gureje, O., Hanon, C., Heinz, A., Isaac, M., et al. (2024) · Sustainable development goals series · doi:10.1007/978-3-031-52179-9_3 · Cited by 1
Schizophrenia and Other Primary Psychotic Disorders
Lawrence, R. E., Becker, I., & McGorry, P. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_104 · Cited by 1
Gutierrez, G., de Jalón, E. G., Aranguren, L., Corrales, A., Gil‐Berrozpe, G. J., Sánchez-Torres, A. M., Librero, J., Peralta, V., & Cuesta, M. J. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116261 · Cited by 1
Crutzen, S., van Os, J., & Castelein, S. (2024) · Psychosis · doi:10.1080/17522439.2024.2430466 · Cited by 1
Koch, T., von Peter, S., Weinmann, S., & Ruiz‐Pérez, G. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116685 · Cited by 1
Will the Treatment Protocols for Schizophrenia be Changing Soon?
Littrell, J. L. (2014) · Social Work in Mental Health · doi:10.1080/15332985.2014.894487 · Cited by 1
The straw man of prescribing in psychiatry
Taylor, D. M. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013581 · Cited by 1
The case against psychiatric drugs
Whitaker, R. B. (2016) · Cadernos Brasileiros de Saúde Mental/Brazilian Journal of Mental Health · doi:10.5007/cbsm.v8i17.69290 · Cited by 1
Roberts, M. (2019) · Mental Health Review Journal · doi:10.1108/mhrj-08-2018-0025 · Cited by 1
A cost-utility analysis of Amisulpride and Paliperidone in the treatment of Schizophrenia
Abdall-Razak, A., Macaulay, A., Tiefenbach, J., Borges, K., Mathema, S., & Zuberi, S. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02343 · Cited by 1
A Brief Guide to Medications for Psychosis
Harris, A. W. F. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815012-2.00023-7 · Cited by 1
Louzã, M. R., & Elkis, H. (2020) · Springer eBooks · doi:10.1007/978-3-030-29081-8_5 · Cited by 1
Psychopharmacological Approaches, Cognitive Enhancement, and Brain Stimulation
Keshavan, M. S., & Eack, S. M. (2019) · Cambridge University Press eBooks · doi:10.1017/9781108163682.009 · Cited by 1
Schizophrenien und andere psychotische Störungen
Leucht, S., Hasan, A., Jäger, M., & Vauth, R. (2019) · Elsevier eBooks · doi:10.1016/b978-3-437-22485-0.00010-5 · Cited by 1
Personal Recovery Within Forensic Settings
Shepherd, A. (2022) · Comprehensive approach to psychiatry · doi:10.1007/978-3-030-98301-7_4 · Cited by 1
Lawrence, R. E. (2022) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgac058 · Cited by 1
Modeling the malleable mental health trajectory – a commentary on Oldehinkel and Ormel (2023)
Tiemeier, H. W. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13766 · Cited by 1
Behdinan, T. (2015) · TSpace (University of Toronto) · Cited by 1
Effekten av vedlikeholdsmedisinering med antipsykotika
Keim, W. (2017) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.17.0469 · Cited by 1
Behaviorally Prescribed Psychopharmacology
Muse, M. D. (2017) · Wiley eBooks · doi:10.1002/9781119152606.ch13 · Cited by 1
Antipsychotics as particular types of sedatives
Moncrieff, J., & Cohen, D. (2019) · Psychological Medicine · doi:10.1017/s0033291719003489 · Cited by 1
Withdrawal-associated relapse is a potential source of bias – Authors' reply
Højlund, M., Kemp, A. F., Haddad, P. M., Neill, J. C., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00288-1 · Cited by 1
Lehmann, P. (2013) · Psychotherapie-Wissenschaft · doi:10.23668/psycharchives.3878
L'idea di recovery: spunti per proseguire nella riflessione
D’Avanzo, B. (2015) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2015-002011
Dose Reduction/Discontinuation for First-Episode Psychosis
Elzinga, W. S., & Schulte, P. F. J. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.4655
Psychiatric Rehabilitation in Residential Treatment Settings
Drake, R. E., Strickler, D. C., & Bond, G. R. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150304-05
Patients need reliable facts and figures about antipsychotics
Lawrie, S. M. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013375
Was verändert sich im Verlauf von 20 Jahren?
Aderhold, V. (2015) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-015-1154-x
Medication management following first-episode psychosis in young people: a developmental approach
Richards, J. (2014) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.113.011767
Arts, K. (2014) · Tijdschrift voor Neuropsychiatrie en Gedragsneurologie · doi:10.1007/s40533-014-0019-9
Miller, B. J., & Matthews, A. M. (2013) · Evidence-Based Mental Health · doi:10.1136/eb-2013-101613
Hunter, N., Glazier, K. A., & McGinn, L. K. (2015) · Psychosis · doi:10.1080/17522439.2015.1044462
Chronic Psychosis and its Prevention
Sfera, A. (2015) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2015.03.00139
research Clinical predictors of therapeutic response to antipsychotics in schizophrenia
Carbon, M., & Correll, C. U. (2014)
Windhager, E., Windhager, I., & Zauner, K. (2015) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Early schizophrenia: skilful management of medication
Cookson, J. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013359
Pharmacological Intervention in First-Episode Psychosis
O'Donoghue, B. N., Walter, M., Huber, C. G., & Lang, U. E. (2016) · Key issues in mental health (Online)/Key issues in mental health (Print) · doi:10.1159/000440923
Valverde, M. A., & Inchauspe, J. A. (2014)
Compulsory Community Treatment and Homicide: Insufficient Evidence Now and in the Future
Hubbeling, D. A. A. (2016) · Psychiatric Services · doi:10.1176/appi.ps.670711
AOT and Long-Term Use of Antipsychotics: In Reply
Barnes, S. S., & Badre, N. (2016) · Psychiatric Services · doi:10.1176/appi.ps.670709
Rodger, J., & Steel, Z. (2016) · Cultural studies of science and medicine · doi:10.1007/978-3-319-24424-2_1
D’Avanzo, B., & Parabiaghi, A. (2016) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2016-002002
Ricerca e impiego degli psicofarmaci
Maone, A. (2016) · RIVISTA SPERIMENTALE DI FRENIATRIA · doi:10.3280/rsf2016-002003
Farina, G., Menditto, E., Corea, G., Manna, S., Pagliaro, C., Troncone, C., Linguiti, C., Orlando, V., Putignano, D., Tari, D. U., et al. (2016)
Questioning the Medical Model of Mental Health
Littrell, J. L. (2017) · Journal of Constructivist Psychology · doi:10.1080/10720537.2016.1268080
The Myth of Mental Illness Revisited: Language Matters
Ernst, F. A. (2016) · Ethical Human Psychology and Psychiatry · doi:10.1891/1559-4343.18.2.92
Sierra, M. D. C. (2017) · Clínica Contemporánea · doi:10.5093/cc2017a23
Hunter, N. (2018) · Springer eBooks · doi:10.1007/978-3-319-91752-8_8
Mutability of Psychosis and Medications
Buckley, P. F. (2018) · Journal of Psychiatry and Brain Science · doi:10.20900/jpbs.20180010
Coercion and the Critical Psychiatrist
Badre, N., Barnes, S. S., Lehman, D., & Steingard, S. (2018) · Springer eBooks · doi:10.1007/978-3-030-02732-2_7
Introductory Chapter: New Directions in the Study of Psychopathology
Woolfolk, R. L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.83717
Pharmakotherapie und andere somatische Behandlungsverfahren (Modul 4a)
Gäebel, W., Hasan, A., & Falkai, P. (2019) · Springer eBooks · doi:10.1007/978-3-662-59380-6_5
Affective and personality disorders in Parkinson's disease premotor phase. Pilot study.
Samushiya, M. A., Ragimova, A. A., Геннадьевна, С. И., M.Yu., M., & Ivannikova, E. I. (2020) · Cognitive Remediation Journal · doi:10.5507/crj.2020.001
Prevention and early intervention in psychotic disorders
Bora, E., Jayaram, M., & Pantelis, C. (2020) · doi:10.1093/med/9780198713005.003.0063
Treatment and management of patients with schizophrenia
McEvoy, J. P., Asuzu, K., Bradford, D. W., Freudenreich, O., & Moyer, K. (2020) · doi:10.1093/med/9780198713005.003.0065
First-Episode & Early Psychosis in Transition-Age Youth
Faraji, P., Camp, C., Elberg, Z., & Usher, C. T. (2021) · Springer eBooks · doi:10.1007/978-3-030-62113-1_14
Metadata
- Authors
- Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J.
- Affiliations
- University Medical Center Groningen (NL)
- Corresponding author
- Wunderink, Lex
- Venue
- JAMA Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-01
- Volume
- 70
- Issue
- 9
- Pages
- 913
- ISSN
- 2168-622X (ISSN-L)
- OpenAlex
- W2125616168
- Cited by
- 567
- References
- 24
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 31 · 2023: 39 · 2022: 37 · 2021: 47 · 2020: 42 · 2019: 71 · 2018: 59 · 2017: 43 · 2016: 65 · 2015: 42 · 2014: 36 · 2013: 8
- FWCI
- 35.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Keywords
- first-episode psychosis, remission, antipsychotic dose reduction, antipsychotic discontinuation, long-term antipsychotic treatment, long-term recovery, functional remission, symptom remission, relapse
- MeSH terms
- Adult, Female, Follow-Up Studies, Humans, Long-Term Care, Male, Psychotic Disorders, Recurrence, Remission Induction, Antipsychotic Agents, Treatment Outcome, Age of Onset, Young Adult, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review